Sagimet Biosciences Eyes U.S. Phase III Acne Study After Positive China DataMarket Beat·2 days ago, 03:01 AMSGMT+1.70%01672-1.75%
Ascletis says FDA clears INDs for obesity candidates ASC36, ASC36_35FDCPUBT·Aug 10 at 05:50 AM01672-1.75%
Ascletis receives FDA clearance to begin Phase III ASC30 programmeWorldPharmaceuticals·Aug 4 at 04:46 AM01672-1.75%
ASCLETIS-B Launches Global Phase III Clinical Study for Obesity Drug ASC30, Expects to File NDA by End-2028AASTOCKS News·Aug 3 at 08:26 PM01672-1.75%
06:55 ETAscletis Announces Initiation of Global Phase III for Oral Small Molecule GLP-1, ASC30 and Positive Preclinical Data for Its First-in-Class Oral Small Molecule GLP-1/GIP/Amylin Fixed-Dose Combinationprnewswire·Aug 3 at 05:56 AM01672-1.75%
Ascletis initiates global Phase III trials of oral obesity drug ASC30 in 4,600 patientsPUBT·Aug 3 at 05:51 AM01672-1.75%
Ascletis Pharma schedules board meeting to review interim results, consider dividendPUBT·Aug 3 at 03:41 AM01672-1.75%
Ascletis Pharma files HKEX next-day disclosure return on share repurchase for cancellationPUBT·Jul 30 at 05:24 AM01672-1.75%
Ascletis Pharma files HKEX next-day disclosure return announcing share repurchase for cancellationPUBT·Jul 28 at 04:06 AM01672-1.75%
06:10 ETAscletis Announces Once-Monthly Subcutaneously Administered GLP-1R/GIPR/GCGR Triple Peptide Agonist, ASC37, Demonstrated Superior Weight Loss in a Diet-Induced Obese Mouse Modelprnewswire·Jul 27 at 05:12 AM01672-1.75%
Ascletis says ASC37 triple agonist posts 88% greater weight loss than tirzepatide in obese micePUBT·Jul 27 at 05:02 AM01672-1.75%
Ascletis Pharma files HKEX next-day return disclosing share repurchase for cancellationPUBT·Jul 27 at 04:07 AM01672-1.75%
Ascletis files HKEX next-day disclosure return reporting share repurchase for cancellationPUBT·Jul 24 at 05:10 AM01672-1.75%
Ascletis Announces Oral Discussion of ASC36_35 FDC Preclinical Data Demonstrating Superior Weight Loss to Eloralintide/Tirzepatide Combination at the 62nd European Association for the Study of Diabetes (EASD) Annual MeetingPR Newswire·Jul 22 at 07:10 PM01672-1.75%
Ascletis Pharma files HKEX next-day disclosure return on share repurchase cancellationPUBT·Jul 21 at 05:07 AM01672-1.75%
